Rosenberg RD - Search Results

1

Monitoring "mini-intensity" anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1+2 levels.

Millenson MM, Bauer KA, Kistler JP, Barzegar S, Tulin L, Rosenberg RD. Millenson MM, et al. Among authors: rosenberg rd. Blood. 1992 Apr 15;79(8):2034-8. Blood. 1992. PMID: 1562730 Free article.

2

Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.

Bauer KA, Mannucci PM, Gringeri A, Tradati F, Barzegar S, Kass BL, ten Cate H, Kestin AS, Brettler DB, Rosenberg RD. Bauer KA, et al. Among authors: rosenberg rd. Blood. 1992 Apr 15;79(8):2039-47. Blood. 1992. PMID: 1562731 Free article.

3

Influence of anticoagulants used for blood collection on plasma prothrombin fragment F1 + 2 measurements.

Bauer KA, Barzegar S, Rosenberg RD. Bauer KA, et al. Among authors: rosenberg rd. Thromb Res. 1991 Sep 15;63(6):617-28. doi: 10.1016/0049-3848(91)90088-e. Thromb Res. 1991. PMID: 1780806

4

Factor IX is activated in vivo by the tissue factor mechanism.

Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Bauer KA, et al. Among authors: rosenberg rd. Blood. 1990 Aug 15;76(4):731-6. Blood. 1990. PMID: 2383653 Free article.

5

Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study.

Furie KL, Rosenberg R, Thompson JL, Bauer K, Mohr JP, Rosner B, Sciacca R, Barzegar S, Thornell B, Costigan T, Kistler JP. Furie KL, et al. Neurology. 2004 Sep 14;63(5):777-84. doi: 10.1212/01.wnl.0000137032.20456.df. Neurology. 2004. PMID: 15365123

6

Coagulation activation following estrogen administration to postmenopausal women.

Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD. Caine YG, et al. Among authors: rosenberg rd. Thromb Haemost. 1992 Oct 5;68(4):392-5. Thromb Haemost. 1992. PMID: 1333098 Clinical Trial.

7

Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease.

Wilkes HC, Meade TW, Barzegar S, Foley AJ, Hughes LO, Bauer KA, Rosenberg RD, Miller GJ. Wilkes HC, et al. Among authors: rosenberg rd. Thromb Haemost. 1992 May 4;67(5):503-6. Thromb Haemost. 1992. PMID: 1519208 Clinical Trial.

8

Role of antithrombin III as a regulator of in vivo coagulation.

Bauer KA, Rosenberg RD. Bauer KA, et al. Among authors: rosenberg rd. Semin Hematol. 1991 Jan;28(1):10-8. Semin Hematol. 1991. PMID: 2017686 Review. No abstract available.

9

Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.

Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD. Mannucci PM, et al. Among authors: rosenberg rd. Blood. 1990 Dec 15;76(12):2540-5. Blood. 1990. PMID: 2265248 Free article. Clinical Trial.

10

Congenital antithrombin III deficiency: insights into the pathogenesis of the hypercoagulable state and its management using markers of hemostatic system activation.

Bauer KA, Rosenberg RD. Bauer KA, et al. Among authors: rosenberg rd. Am J Med. 1989 Sep 11;87(3B):39S-43S. doi: 10.1016/0002-9343(89)80530-3. Am J Med. 1989. PMID: 2679069 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

343 results

Search Page

Filters